BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth

Core Insights - Bausch Health Companies Inc. (BHC) reported mixed results for Q4 2025, with adjusted EPS of $1.08 missing estimates but total revenues of $2.8 billion exceeding expectations, leading to a decline in share price during after-hours trading [1][6]. Financial Performance - Adjusted EPS of $3.73 for 2025 missed the Zacks Consensus Estimate of $3.90 and decreased from $3.75 in 2024 [11]. - Total revenues for 2025 were $10.3 billion, up 7% from 2024, surpassing the Zacks Consensus Estimate of $10.17 billion [11]. - Q4 total revenues increased by 9% year over year, reaching $2.8 billion, beating the Zacks Consensus Estimate of $2.7 billion [1][6]. Segment Performance - Bausch Health segment revenues were $1.4 billion, up 9% year over year, with Salix revenues at $693 million, also up 9% [3][4]. - Xifaxan, a key product in the Salix division, generated $607 million in sales, a 10% increase year over year [4]. - International revenues totaled $306 million, up 10% year over year, driven by growth in EMEA markets [7]. - Bausch + Lomb revenues reached $1.4 billion, up 10% year over year, with growth across vision care, surgical, and pharmaceuticals [10]. Guidance and Future Outlook - BHC expects 2026 revenues to be between $10.625 billion and $10.875 billion, above the consensus estimate of $10.49 billion [15]. - Excluding Bausch + Lomb, revenues are projected to be between $5.250 billion and $5.400 billion, while Bausch + Lomb revenues are expected to be between $5.375 billion and $5.475 billion [15]. Pipeline Developments - BHC announced the failure of the late-stage RED-C clinical program, which did not meet its primary endpoint despite the compound being safe [12][13]. - The company received Breakthrough Therapy Designation for larsucosterol for treating Alcohol-Associated Hepatitis [13]. - The Clear and Brilliant Touch program for skin rejuvenation is advancing with multiple international approvals [14]. Strategic Moves - BHC recently acquired Shibo's full-service aesthetics distribution business in China, enhancing its geographic footprint and access to a growing customer base [17]. - The company continues to face significant debt, with total obligations amounting to $20.2 billion as of December 31, 2025 [18].